| dc.identifier.citation | Khachaturian, A.S. and Hayden, K.M. and Devlin, J.W. and Fleisher, L.A. and Lock, S.L. and Cunningham, C. and Oh, E.S. and Fong, T.G. and Fick, D.M. and Marcantonio, E.R. and Iyengar, V. and Rockwood, K. and Kuchel, G.A. and Eckenhoff, R.G. and MacLullich, A.M.J. and Jones, R.N. and Davis, D. and D'Antonio, P.M. and Fargo, K.N. and Albert, M.S. and Williamson, J.D. and Ling, S.M. and Weiss, J. and Karlawish, J. and Petersen, R.C. and Blazer, D.G. and Khachaturian, Z.S. and Inouye, S.K., International drive to illuminate delirium: A developing public health blueprint for action, Alzheimer's and Dementia, 16, 5, 2020, 711-725 | en |
| dc.description.abstract | Presently, there is a clear societal and demographic imperative to
identify and deliver interventions that are effective in reducing
dementia. With the high failure rate of compounds in clinical trials, and
with pharmaceutical development cycles typically lasting decades,
a hybrid person-with-dementia-centered approach that precisely inte-
grates pharmaceutical, non-pharmaceutical, lifestyle modification, and care
interventions for the individual may offer more immediate results for
reducing dementia burden. One important, tangible, and overlooked
strategy with this proposed approach may be through the recognition
and prevention of delirium. | en |
